Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Momenta

- PMLiVE

J&J puts pressure on rivals with new Erleada okay in prostate cancer

FDA previously granted priority review in this indication

- PMLiVE

J&J’s Tremfya filed for approval in US for psoriatic arthritis

Seeking share of increasingly competitive psoriasis market

- PMLiVE

J&J’s ponesimiod tops Aubagio in head-to-head MS trial

Sets up regulatory filings and possible approval next year

- PMLiVE

J&J found liable in first opioid mis-marketing verdict

Oklahoma challenge a milestone, but company will appeal

- PMLiVE

Lilly psoriasis drug beats J&J’s Tremfya in head-to-head trial

Shifting expectations in psoriasis outcomes

- PMLiVE

FDA clears first-line use for J&J’s myeloma drug Darzalex

Frontline approval for Janssen's Darzalex a milestone in march towards blockbuster status

- PMLiVE

Daily Brief: Deal done, Takeda to cut $1.4bn, Brexit latest, Valeant rebrands

A rapid round-up of the top pharma, biotech and healthcare news

J&J launches digital skincare challenge

Seeks start-ups focused on tackling areas such as skin health adherence treatment

Eli Lilly HQ

Lilly pays Nektar $150m upfront for phase I autoimmune drug

Will add another $250m if candidate meets development objectives

- PMLiVE

IMI aims €130m at medical research’s unanswered questions

Targets for the partnership’s latest funding round including Alzheimer’s

- PMLiVE

J&J gets CHMP backing for broader Darzalex use

Recommendation for earlier-stage approval could see multiple myeloma drug reach blockbuster sales

Sanofi reception

Sanofi/Regeneron bag first approval for Actemra rival sarilumab

Competition to Roche’s blockbuster RA therapy heats up as Canada is first to licence new drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links